UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity

Clinical therapeutics, 2000-06, Vol.22 (6), p.685-708

Kakuda, Thomas N.

2000

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

PloS one, 2018-10, Vol.13 (10), p.e0204974

2018

Volltextzugriff (PDF)

Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment

Journal of clinical pharmacology, 2023-06, Vol.63 (6), p.732-741

2023

Volltextzugriff (PDF)

The Cellular Pharmacology of Nucleoside- and Nucleotide-Analogue Reverse-Transcriptase Inhibitors and Its Relationship to Clinical Toxicities

Clinical infectious diseases, 2004-03, Vol.38 (5), p.743-753

2004

Volltextzugriff (PDF)

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

The Journal of infectious diseases, 2019-01, Vol.219 (2), p.177-185

2019

Volltextzugriff (PDF)

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

Gastroenterology (New York, N.Y. 1943), 2019-04, Vol.156 (5), p.1392-1403.e7

2019

Volltextzugriff (PDF)

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

Journal of viral hepatitis, 2018-06, Vol.25 (6), p.631-639

2018

Volltextzugriff (PDF)

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4228-4232

2008

Volltextzugriff (PDF)

Pharmacokinetics of once‐daily darunavir/ritonavir in HIV‐1–infected pregnant women

HIV medicine, 2016-10, Vol.17 (9), p.643-652

2016

Volltextzugriff (PDF)

Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials

Antimicrobial Agents and Chemotherapy, 2011-05, Vol.55 (5), p.2290-2296

2011

Volltextzugriff (PDF)

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

HIV medicine, 2014-01, Vol.15 (1), p.50-56

2014

Volltextzugriff (PDF)

Sb-mediated growth of high-density InAs quantum dots and GaAsSb embedding growth by MBE

Applied surface science, 2008-10, Vol.254 (24), p.8050-8053

2008

Volltextzugriff (PDF)

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

AIDS (London), 1999-11, Vol.13 (16), p.2311-2312

1999

Volltextzugriff (PDF)

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies

Journal of antimicrobial chemotherapy, 2014-03, Vol.69 (3), p.728-734

2014

Volltextzugriff (PDF)

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

AIDS (London), 2002-03, Vol.16 (4), p.551-560

2002

Volltextzugriff (PDF)

Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two‐panel, two‐way, two‐period, randomized trial

HIV medicine, 2013-08, Vol.14 (7), p.421-429

2013

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients

Clinical pharmacology and therapeutics, 2010-11, Vol.88 (5), p.695-703

2010

Volltextzugriff (PDF)

Is human muscle spindle afference dependent on perceived size of error in visual tracking?

Experimental brain research, 1997-04, Vol.114 (2), p.246-254

1997

Volltextzugriff (PDF)

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2

Journal of hepatology, 2024-09, Vol.81 (3), p.404-414

2024

Volltextzugriff (PDF)

Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease Inhibitors

Clinical infectious diseases, 2000-06, Vol.30 (Supplement-2), p.S151-S159

2000

Volltextzugriff (PDF)

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

AIDS (London), 2003-10, Vol.17 (15), p.2159-2168

2003

Volltextzugriff (PDF)

Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?

Current opinion in infectious diseases, 2000-02, Vol.13 (1), p.5-11

2000

Volltextzugriff (PDF)

Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Clinical pharmacokinetics, 2017-05, Vol.56 (5), p.525-536

2017

Volltextzugriff (PDF)

Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents

AIDS (London), 2012-02, Vol.26 (4), p.447-455

2012

Volltextzugriff (PDF)

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

HIV medicine, 2015-05, Vol.16 (5), p.288-296

2015

Volltextzugriff (PDF)

1 – 25 von 297

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(248)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment

The Cellular Pharmacology of Nucleoside- and Nucleotide-Analogue Reverse-Transcriptase Inhibitors and Its Relationship to Clinical Toxicities

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Pharmacokinetics of once‐daily darunavir/ritonavir in HIV‐1–infected pregnant women

Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

Sb-mediated growth of high-density InAs quantum dots and GaAsSb embedding growth by MBE

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two‐panel, two‐way, two‐period, randomized trial

Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients

Is human muscle spindle afference dependent on perceived size of error in visual tracking?

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2

Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease Inhibitors

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals

Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?

Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

Suchergebnisse filtern